Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs ... highlighting. This does not affect our editorial ...

What risks does the company face in terms of manufacturing and supply constraints? Novo Nordisk has been grappling with supply constraints for its popular GLP-1 drugs. These constraints have led ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The drug has also been evaluated in adults and adolescents. Following the positive data, Novo Nordisk expects to make its Mim8 regulatory submission in 2025. Haemophilia A is a rare blood disorder ...

A drug that Novo Nordisk acquired to expand its prospects ... As a large molecule that does not easily penetrate the blood brain barrier, this antibody should avoid sparking the neuropsychiatric ...